<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Avalo Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/avalo-therapeutics-inc</link>
<description>Latest news and press releases for Avalo Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/avalo-therapeutics-inc" rel="self" type="application/rss+xml" />
<item>
<title>Avalo Therapeutics Purchases Optional Milestone Buyout</title>
<link>https://6ix.com/company/avalo-therapeutics-inc/news/avalo-therapeutics-purchases-optional-milestone-buyout</link>
<guid isPermaLink="true">https://6ix.com/company/avalo-therapeutics-inc/news/avalo-therapeutics-purchases-optional-milestone-buyout</guid>
<pubDate>Tue, 28 Apr 2026 11:00:00 GMT</pubDate>
<description>WAYNE, Pa., April 28, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated inflammatory diseases, today announced that it has entered into a Milestone Buyout Option and Amendment Agreement (the “Buyout Agreement”) related to the company’s prior acquisition of AlmataBio, Inc. in March of 2024. Pursuant to the Buyout Agreement, Avalo has agreed to pay $2.25 million</description>
</item>
<item>
<title>Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates</title>
<link>https://6ix.com/company/avalo-therapeutics-inc/news/avalo-therapeutics-reports-2025-financial-results-and-recent-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/avalo-therapeutics-inc/news/avalo-therapeutics-reports-2025-financial-results-and-recent-business-updates</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>Topline data expected from Phase 2 LOTUS trial of abdakibart (AVTX-009) for the treatment of hidradenitis suppurativa in the second quarter of 2026Cash, cash</description>
</item>
<item>
<title>Avalo Therapeutics to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/avalo-therapeutics-inc/news/avalo-therapeutics-participate-upcoming-investor-120000876</link>
<guid isPermaLink="true">https://6ix.com/company/avalo-therapeutics-inc/news/avalo-therapeutics-participate-upcoming-investor-120000876</guid>
<pubDate>Wed, 04 Feb 2026 12:00:00 GMT</pubDate>
<description>WAYNE, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Guggenheim Emerging Outlook: Biotech Summit 2026Fireside ChatFebruary 11, 2026, at 10:00 am ET Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFireside ChatFebruary 25, 2026, at 1</description>
</item>
<item>
<title>Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/avalo-therapeutics-inc/news/avalo-therapeutics-announces-inducement-grants-213000838</link>
<guid isPermaLink="true">https://6ix.com/company/avalo-therapeutics-inc/news/avalo-therapeutics-announces-inducement-grants-213000838</guid>
<pubDate>Mon, 17 Nov 2025 21:30:00 GMT</pubDate>
<description>WAYNE, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to three new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 114,000 shares of common stock (the “Options”) as inducement</description>
</item>
<item>
<title>Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates</title>
<link>https://6ix.com/company/avalo-therapeutics-inc/news/avalo-therapeutics-reports-third-quarter-120000198</link>
<guid isPermaLink="true">https://6ix.com/company/avalo-therapeutics-inc/news/avalo-therapeutics-reports-third-quarter-120000198</guid>
<pubDate>Thu, 06 Nov 2025 12:00:00 GMT</pubDate>
<description>Completed enrollment in Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa; topline data expected mid-2026Appointed Kevin Lind to Board of DirectorsExpanded leadership team with key appointments in business development and human resourcesCash and short-term investments of approximately $112 million as of September 30, 2025 expected to provide runway into 2028 WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotech</description>
</item>
<item>
<title>Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa</title>
<link>https://6ix.com/company/avalo-therapeutics-inc/news/avalo-therapeutics-announces-completion-enrollment-110000751</link>
<guid isPermaLink="true">https://6ix.com/company/avalo-therapeutics-inc/news/avalo-therapeutics-announces-completion-enrollment-110000751</guid>
<pubDate>Wed, 29 Oct 2025 11:00:00 GMT</pubDate>
<description>WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that the Company has completed enrollment in its Phase 2 LOTUS trial of AVTX-009 in adults with hidradenitis suppurativa (HS). The LOTUS trial exceeded target enrollment of 222 patients with approximately 250 patients enrolled. Topline data from the trial is exp</description>
</item>
<item>
<title>Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources</title>
<link>https://6ix.com/company/avalo-therapeutics-inc/news/avalo-therapeutics-expands-leadership-team-110000658</link>
<guid isPermaLink="true">https://6ix.com/company/avalo-therapeutics-inc/news/avalo-therapeutics-expands-leadership-team-110000658</guid>
<pubDate>Wed, 01 Oct 2025 11:00:00 GMT</pubDate>
<description>WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been named Chief Business Officer, and Ashley Ivanowicz has joined as Senior Vice President, Human Resources. “We are delighted to welcome Taylor and Ashley to Avalo as we enter a</description>
</item>
<item>
<title>Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors</title>
<link>https://6ix.com/company/avalo-therapeutics-inc/news/avalo-therapeutics-appoints-kevin-r-110000663</link>
<guid isPermaLink="true">https://6ix.com/company/avalo-therapeutics-inc/news/avalo-therapeutics-appoints-kevin-r-110000663</guid>
<pubDate>Mon, 22 Sep 2025 11:00:00 GMT</pubDate>
<description>WAYNE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the appointment of Kevin R. Lind to its Board of Directors. Mr. Lind brings more than 20 years of leadership in capital markets, strategy, business development and company building, including most recently guiding Longboard Pharmaceuticals to a multi-billion-do</description>
</item>
<item>
<title>Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates</title>
<link>https://6ix.com/company/avalo-therapeutics-inc/news/avalo-reports-second-quarter-2025-110000353</link>
<guid isPermaLink="true">https://6ix.com/company/avalo-therapeutics-inc/news/avalo-reports-second-quarter-2025-110000353</guid>
<pubDate>Thu, 07 Aug 2025 11:00:00 GMT</pubDate>
<description>Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected mid-2026Rita Jain, M.D. appointed to Board of DirectorsCash and short-term investments of approximately $113 million as of June 30, 2025 expected to provide runway into 2028 WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases,</description>
</item>
<item>
<title>Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors</title>
<link>https://6ix.com/company/avalo-therapeutics-inc/news/avalo-therapeutics-announces-appointment-rita-110000192</link>
<guid isPermaLink="true">https://6ix.com/company/avalo-therapeutics-inc/news/avalo-therapeutics-announces-appointment-rita-110000192</guid>
<pubDate>Wed, 18 Jun 2025 11:00:00 GMT</pubDate>
<description>WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors. “We are pleased to welcome Dr. Jain to Avalo’s Board of Directors,” said Michael Heffernan, Chairman of the Board. “Rita’s extensive experience spanning clinical development, regulatory strategy, and executive leadership at multiple development-s</description>
</item>
<item>
<title>Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates</title>
<link>https://6ix.com/company/avalo-therapeutics-inc/news/avalo-reports-first-quarter-2025-financial-results-and-recent-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/avalo-therapeutics-inc/news/avalo-reports-first-quarter-2025-financial-results-and-recent-business-updates</guid>
<pubDate>Mon, 12 May 2025 04:00:00 GMT</pubDate>
<description>Mike Heffernan appointed as Chairman of the Board Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in</description>
</item>
<item>
<title>Avalo Therapeutics to Participate in The Citizens Life Sciences Conference</title>
<link>https://6ix.com/company/avalo-therapeutics-inc/news/avalo-therapeutics-participate-citizens-life-110000521</link>
<guid isPermaLink="true">https://6ix.com/company/avalo-therapeutics-inc/news/avalo-therapeutics-participate-citizens-life-110000521</guid>
<pubDate>Wed, 30 Apr 2025 11:00:00 GMT</pubDate>
<description>WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will present at the Citizens Life Sciences Conference in New York on Thursday, May 8, 2025, at 3:00 pm ET. Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeuti</description>
</item>
<item>
<title>Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board</title>
<link>https://6ix.com/company/avalo-therapeutics-inc/news/avalo-therapeutics-appoints-michael-heffernan-110000895</link>
<guid isPermaLink="true">https://6ix.com/company/avalo-therapeutics-inc/news/avalo-therapeutics-appoints-michael-heffernan-110000895</guid>
<pubDate>Wed, 26 Mar 2025 11:00:00 GMT</pubDate>
<description>WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors (“Board”). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. “We are thrilled to welcome Michael to Avalo’s Bo</description>
</item>
<item>
<title>Avalo Reports 2024 Financial Results and Recent Business Updates</title>
<link>https://6ix.com/company/avalo-therapeutics-inc/news/avalo-reports-2024-financial-results-110000409</link>
<guid isPermaLink="true">https://6ix.com/company/avalo-therapeutics-inc/news/avalo-reports-2024-financial-results-110000409</guid>
<pubDate>Thu, 20 Mar 2025 11:00:00 GMT</pubDate>
<description>Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business up</description>
</item>
<item>
<title>Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer</title>
<link>https://6ix.com/company/avalo-therapeutics-inc/news/avalo-therapeutics-appoints-jennifer-riley-as-chief-strategy-officer</link>
<guid isPermaLink="true">https://6ix.com/company/avalo-therapeutics-inc/news/avalo-therapeutics-appoints-jennifer-riley-as-chief-strategy-officer</guid>
<pubDate>Thu, 02 Jan 2025 05:00:00 GMT</pubDate>
<description>WAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on</description>
</item>
<item>
<title>Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants</title>
<link>https://6ix.com/company/avalo-therapeutics-inc/news/avalo-therapeutics-receives-dollar694-million-in-proceeds-from-the-full-exercise-of-private-placement-warrants</link>
<guid isPermaLink="true">https://6ix.com/company/avalo-therapeutics-inc/news/avalo-therapeutics-receives-dollar694-million-in-proceeds-from-the-full-exercise-of-private-placement-warrants</guid>
<pubDate>Tue, 12 Nov 2024 05:00:00 GMT</pubDate>
<description>Proceeds from the full exercise of warrants issued in the first quarter of 2024 private placement bring the total gross proceeds from the transaction to $185</description>
</item>
<item>
<title>Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates</title>
<link>https://6ix.com/company/avalo-therapeutics-inc/news/avalo-reports-third-quarter-2024-financial-results-and-recent-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/avalo-therapeutics-inc/news/avalo-reports-third-quarter-2024-financial-results-and-recent-business-updates</guid>
<pubDate>Thu, 07 Nov 2024 05:00:00 GMT</pubDate>
<description>Dosed first patient in Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa (HS), with topline data expected in 2026Cash position of</description>
</item>
<item>
<title>Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa</title>
<link>https://6ix.com/company/avalo-therapeutics-inc/news/avalo-announces-first-patient-dosed-in-phase-2-lotus-trial-of-avtx-009-for-the-treatment-of-hidradenitis-suppurativa</link>
<guid isPermaLink="true">https://6ix.com/company/avalo-therapeutics-inc/news/avalo-announces-first-patient-dosed-in-phase-2-lotus-trial-of-avtx-009-for-the-treatment-of-hidradenitis-suppurativa</guid>
<pubDate>Tue, 08 Oct 2024 04:00:00 GMT</pubDate>
<description>Global study in approximately 180 adults with hidradenitis suppurativa to assess the efficacy and safety of two dose regimens of AVTX-009 compared to</description>
</item>
<item>
<title>Avalo Announces Participation in September Investor Conferences</title>
<link>https://6ix.com/company/avalo-therapeutics-inc/news/avalo-announces-participation-in-september-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/avalo-therapeutics-inc/news/avalo-announces-participation-in-september-investor-conferences</guid>
<pubDate>Wed, 04 Sep 2024 04:00:00 GMT</pubDate>
<description>WAYNE, Pa. and ROCKVILLE, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief</description>
</item>
<item>
<title>Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/avalo-therapeutics-inc/news/avalo-reports-second-quarter-2024-financial-results-and-provides-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/avalo-therapeutics-inc/news/avalo-reports-second-quarter-2024-financial-results-and-provides-business-updates</guid>
<pubDate>Mon, 12 Aug 2024 04:00:00 GMT</pubDate>
<description>Expects to enroll first patient in Phase 2 LOTUS Trial of AVTX-009 in hidradenitis suppurativa in the second half of 2024Appointed Dr. Mittie Doyle as Chief</description>
</item>
</channel>
</rss>